HBCs that are estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) are considered better-differentiated tumors with more a favorable prognosis, while estrogen receptor-negative (ER-) and progesterone receptor-negative (PR-) HBC are usually related to more aggressive tumor and worse outcomes [111]. This evidence concerns the gene ESR1 and neoplasm.